PATENT/Docket No.: 6142.N CP

Serial No.: 09/213,888

Page No. 1

Rich 3.00

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington D.C. 20231.

Julie K. Lyons, Legal Assistant

Signature

Name of Person Mailing Paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1645

Examiner

S. Turner

Applicant(s)

ME Gurney, AM Pauley and J Li

Serial No.

09/213,888

Filed

17 December 1998

For

Human Sel-10 Polypeptides and Polynucleotides that Encode Them

Commissioner of Patents and Trademarks

Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL UNDER 37 CFR 1.97 AND 1.98

Sir:

Information Disclosed. The information disclosed consists of the following:

- [X] Form PL-1449. Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.
 - [] At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:

|--|

- [] provided in a communication enclosed with this paper;
- [] provided in the International Search Report enclosed with this paper; and/or
- [] not necessary as all of the references cited are in the English language.

PATENT/Docket No.: 6142.N CP

Serial No.: 09/213,888

Page No. 2

[] Disclosure from Predecessor Application. Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed , the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).

Basis for Consideration. This information disclosure statement is entitled to consideration by the Office under:

- [] §1.97(b), as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.
- [X] §1.97(c), as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311.

 Consideration of this information disclosure statement at this time is requested for the reason checked below:
 - [X] Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$240.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.
 - [] A statement as specified in 37 CFR 1.97(e) below.
- [] §1.97(d), as being filed after the period specified in §1.97(c), but on or before payment of the issue fee and is accompanied by:
 - [] Authorization to charge Deposit Account No. 21-0718 the fee set forth in §1.17(i), \$130.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.
 - [] A petition requesting consideration of the information disclosure statement; and
 - [] A statement as specified in 37 CFR 1.97 (e) below.
- [] §1.97(e), this is a supplemental information disclosure statement. A prior information disclosure statement has already been filed. Applicant certifies, as provided in 37 CFR 1.97 (e), that

PATENT/Docket No.: 6142.N CP

Serial No.: 09/213,888

Page No. 3

[] Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

[] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

Disclaimer. In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,

Edward F. Rehberg, Attorney

Registration No. 34,703

Pharmacia & Upjohn Company Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49001

Telephone No. (616) 833-7829 or (616) 833-9500 Telefax No. (616) 833-8897 or (616) 833-2316

Attachment(s)

[X] Form 1449 with copies of reference(s)

[] Form 1449 from predecessor application (no references)

[] Communication providing concise explanation of relevance

[X] International Search Report

·				Atty.	Docket No.		Se	erial No.		
				6142.N CP			09/213,888			
LIST OF		RENCES CITES e several sheets if nece	D BY APPLICANT							
				Applicant Adele M. Pauley, Mark E. Gurney, Jinhe Li						
				Filing Date 19 Dec., 1997			Group 16	541		
<u> </u>	······································		U.S. PA	TENT DOCUM	ENTS					
Examiner Initial		Document Number	Date						Filing Date If Appropriate	
	AA									
	AB									
	AC									
	AD							,		
			FOREIGN	PATENT DOC	UMENTS	· ₁		r		
		Document Number	Date	Country	Country Class		lass Subclass	Translation		
								Yes	No	
	AE	WO 97/11956	3 April 1997	World		C07H	21/04	Х		
	AF									
	AG					<u></u>				
			OTHER PRIOR ART (I	ncluding Author, Tit	e, Date, Pertinent	Pages, Etc.)			
	AH	F55B12.3 GenPep Report (WMBL locus CEF55B12, accession z79757)								
	AI	D.R. Borchelt, G. Thinakaran, C.B. Eckman, M.K. Lee, F. Davenport, T. Ratovitsky, CM. Prada, G. Kim, S. Seekins, D. Yager, H.H. Slunt, R. Wang, M. M. Seeger, A.I. Levey, S.E. Gandy, N.G. Copeland, N.A. Jenkins, D.L. Price, S.G. Younkin, S.S. Sisodia, "Familial Alzheimer's Disease-Linked Presentlin 1 Variants Elevate A\(\beta\)1-42/1-40 Ratio In Vitro and In Vivo," Neuron, 1996, 17:1005-1013								
	AJ	Price, S.S. Sisc	T. Ratovitski, J. van L dia, "Accelerated Amyl ilin 1 and Amyloid Pre	loid Deposition	in the Brains o	f Transg	kins, N.G. Copeland, D.L. genic Mice Coexpressing 9-945			
	AK	Seubert, A. Da J. Rommens, S Alzheimer's dis	vis, D. Kholodenko, R. J. Kim, D. Schenk, P. F	Motter, R. She raser, P. St Geo on of 42-residue	rrington,l B. P orge Hyslop, D	erry, H. .J. Selko	Anson-Wood, M. Lee, P. Yao, R. Strome, I. Lieberburg, oe, "Mutant presentlins of both transfected cells and lisny, D.J. Selkoe, M. Seeger, ouron, 1996, 17:1023-1030			
	AL	A. Doan, G. Th S.E. Gandy, D	ninakaran, D.R. Borche L. Price, S.S. Sisodia,	elt, H.H. Slunt, "Protein Topolo	T. Ratovitsky, gy of Presenili	M. Podli n 1," Neu				
	AM	Yager, D. Mor	K. Duff, C. Eckman, C. Zehr, X. Yu, CM. Prada, J. Perez-Tur, M. Hutton, L. Buee, Y. Harigaya, D. Yager, D. Morgan, M.N. Gordon, L. Holcomb, L. Refolo, B. Zenk, J. Hardy, S. Younkin, "Increased amyloid-β42(43) in brains of mice expressing mutant presentlin 1," Nature, 1996, 383:710-713						, D. ed	
	AN	I. Greenwald, elegans," Natu	nwald, G. Seydoux, "Analysis of gain-of-function mutations of the lin-12 gene of Caenorhabditis ," Nature, 1990, 346: 197-9						bditis	
	AO	M. Hochstrasser, "Ubiquitin-dependent protein degradation," Annual Review of Genetics, 1996, 30:405-439						30:405-		

	RENCES CITED BY APPLICANT Use several sheets if necessary)		Docket No. 42.N CP	Serial No. 09/213,888		
		Applicant	Adele M. Pauley, M	lark E. Gurney, Jinhe Li		
		Filing Date	19 Dec., 1997	Group 1641		
AP	E.J.A. Hubbard, G. Wu, J. Kitajewski, Caenorhabditis elegans, encodes a men 11: 3182-3193					
AQ	AQ T.W. Kim, W.H. Pettingell, O.G. Hallmark, R.D. Moir, W. Wasco, R.E. Tanzi, "Endoproteolytic Cleaves and Proteasomal Degradation of Presentlin 2 in Transfected Cells," Journal of Biological Chemistry, 1 272: 11006-11010					
AR	D.M. Kovacs, H.J. Fausett, K.J. Page, Hallmark, R. Mancini, K.M. Felsenste presenilins 1 and 2: Neronal expressio mammalian cells," Nat. Med., 1996, 2:	in, B.T. Hyman, n in brain and i	R.E. Tanzi, W. Wasco	o,"Alzheimer-associated		
AS	D. Levitan, T.G. Doyle, D. Brousseau, "Assessment of normal and mutant hun Acad. Sci. USA, 1996, 93: 14940-4					
AT	D. Levitan, I. Greenwald, "Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene," Nature, 1995, 377: 351-4					
AU	E. Levy-Lahad, W. Wasco, P. Poorkaj, D.M. Romano, J. Oshima, W.H. Pettingell, CE. Yu, P.D. Jondro, S.D. Schmidt, K. Wang, A.C. Crowley, YH. Fu, S.Y. Guenette, D. Galas, E. Nemens, E.M. Wijsman, T.D. Bird, G.D. Schellenberg, R.E. Tanzi, "Candidate Gene for the Chromosome 1 Familial Alzheimer's Disease Locus," Science, 1995, 269: 973-977					
AV	J. Li, J. Ma, H. Potter, "Identification and expression analysis of a potential familial Alzheimer disease gene on chromosome 1 related to AD3," Proc. Natl. Acad. Sci. U.S.A., 1995, 92:12180-12184					
AW	M. Mercken, H. Takahashi, T. Honda, Takashima, "Characterization of humo Evidence that Alzheimer mutations aff	ın presenilin 1 u	sing N-terminal speci	fic monoclonal antibodies:		
AX	M. Mullan, F. Crawford, K. Axelman, mutation for probable Alzheimer's dise 1992 Aug, 1(5):345-7					
AY	J. Perez-Tur, S. Froelich, G. Prihar, R. Crook, M. Baker, K. Duff, M. Wragg, F. Busfield, C. Lendon, R.F. Clark, P. Roques, R.A. Fuldner, J. Johnston, R. Cowburn, C. Forsell, K. Axelman, L. Lilius, H. Houlden, E. Karran, G.W. Roberts, M. Rossor, M.D. Adams, J. Hardy, A. Goate, L. Lannfelt, M. Hutton, "A Mutation in Alzheimer's disease destroying a splice acceptor site in the presentiin-1 gene," Neuroreport, 1995, 7:297-301					
AZ	E.I. Rogaev, R. Sherrington, E.A. Roga T. Tsuda, L. Mar, S. Sorbi, B. Nacmais P.E. Fraser, J.M. Rommens, P.H. St G missense mutations in a gene on chrom 1995, 376: 775-778	s, S. Piacentini, eorge-Hyslop, "	L. Amaducci, I. Chum Familial Alzheimer's c	akov, D. Cohen, L. Lannfelt, lisease in kindreds with		
ВВ	D. Scheuner, C. Eckman, M. Jensen, X. Kukull, E. Larson, E. Levy-Lahad, M. Wasco, L. Lannfelt, D. Selkoe, S. Your plaques of Alzheimer's disease is increased familial Alzheimer's disease," Nat. Me	Viitanen, E. Pea akin, "Secreted a ased in vivo by t	skind, P. Poorkaj, G. S myloid β-protein simil he presenilin 1 and 2 d	chellenberg, R. Tanzi, W. Lar to that in the senile		

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				Docket No. 42.N CP	Serial No. 09/213,888		
			Applicant Adele M. Pauley, Mark E. Gurney, Jinhe				
			Filing Date	19 Dec., 1997	Group 1641		
	BC R. Sherrington, E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, M. Ikeda, H. Chi, C. Lin, G. Li, K. Holman, T. Tsuda, L. Mar, JF. Foncin, A.C. Bruni, M.P. Montesi, S. Sorbi, I. Rainero, L. Pinessi, L. Nee, I. Chumakov, D. Pollen, A. Brookes, P. Sanseau, R.J. Polinsky, W. Wasco, H.A.R. Da Silva, J.L. Haines, M.A. Pericak-Vance, R.E. Tanzi, A.D. Roses, P.E. Fraser, J.M. Rommens, P.H. St George-Hyslop, "Cloning of a gene bearing missense mutations in early-onset familial Alzheimed disease," Nature, 1995, 375: 754-760						
	BD M. Sundaram, I. Greenwald, "Genetic and Phenotypic Studies of Hypomorphic lin-12 Mutants in Caenorhabditis elegans," Genetics, 1993, 135: 755-763						
	BE M. Sundaram, I. Greenwald, "Suppressors of a lin-12 Hypomorph Define Genes That Interact With Both lin-12 and glp-1 in Caenorhabditis elegans," Genetics, 1993, 135: 765-83						
Examiner			Date Considered				

				1	Docket No.		Serial No.		
ו זמשו בי	LIST OF REFERENCES CITED BY APPLICANT			61	142.N CP		0:	9/213, 888	
LIST OF		IKENCES CITE Use several sheets if nec							
				Applicant ME Gurney, et. al.					
				Filing Date	6/19/1999		Group 1	647	
			U.S. PA	ATENT DOCUMI	ENTS				
Examiner Initial		Document Number	Date	Name		Class	Subclass	Filing Date Subclass If Appropriate	
	AA								
	AB								
	AC								
	AD				 				
	AE			<u> </u>					
	AF								
	AG								
	AH								
	AI								
			FOREIGN	PATENT DOCU	JMENTS				
		Document Number	Date	Country		Class	Subclass	Translati	ion
								Yes	No
	AJ								<u> </u>
	AK			-					
	AL								
	AM								
	AN			<u> </u>	····				<u> </u>
		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	OTHER PRIOR ART (In	cluding Author, Title,	Date, Pertinent I	Pages, Etc.)	 		
	AO	Choh, PNAS 77(6): 3211-14, 1980							
	AP	Jenkins, PCR M	lethods and Appl., S77-8	32, 1994					
	AQ	Crooke, Antises	ne & Nucl. Acid Drug D	ev., 8:115-22, 199	8				
	AR	Genbank Access	sion No. AA625610; Octo	ber 15, 1997					
	AS	Genbank H2296	52 July 6, 1995						
	AT	Genbank H343	71 July 19, 1995						
	AU	Sambrook et al.	, Cold Spring Harbor La	bs, 17-1-17.44, 19	989				
	AV	Skolnick et al., Trends in Biotech., 18(1):34-39, 2000							
	AW	Yochem et al., J. Mol. Biol., 195:233-45							

Y APPLICANT		Docket No. 42.N CP	Serial No. 09/213, 888		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Applicant Filing Date	ME Gurney, et. al. 6/19/1999	Group 1647		
Examiner	Date Considered				